| Private Placement / Financing Transactions
Augmedics: The company raised $82.5 million of Series D venture funding in a deal led by CPMG on June 27, 2023. H.I.G. Capital, Revival Healthcare Capital, Evidity Health Capital, and Almeda Ventures also participated in the round. The company is a developer of an augmented-reality surgical visualization system designed to assist in viewing the patient’s anatomy through skin and tissue during surgeries.
Presidio Medical: The company raised $72 million of Series C venture funding in a deal led by Deerfield Management on June 26, 2023, putting the company’s pre-money valuation at $58 million. Action Potential Venture Capital, Invus Opportunities and ShangBay Capital also participated in the round. The company is a developer of a neuromodulation platform designed to establish a class of therapeutic medical devices.
K36 Therapeutics: The company raised $70 million of Series B venture funding in a deal led by Nextech Invest on June 28, 2023, putting the company’s pre-money valuation at $65 million. Eight Roads, Bristol-Myers Squibb, Atlas Venture and other undisclosed investors also participated in the round. The company is an operator of a biotechnology business intended to develop small molecule therapeutics.
Evommune: The company raised $57.5 million of Series B venture funding in a deal led by EQT Life Sciences, SymBiosis Capital Management and Arix Bioscience on June 28, 2023. Andera Partners and 4 other investors also participated in the round. The company is a developer of tissue-based transformative medicines designed to treat inflammatory diseases.
Carthera: The company raised EUR 37.5 million of Series B venture funding from Supernova Invest, Pancakes Partners, and European Innovation Council Fund on June 27, 2023. Relyens also participated in the round. The company is an operator of a clinical-stage medical technology business intended to develop ultrasound-based devices designed to treat brain disorders.
NanoCellect Biomedical: The company raised $28.9 million of venture funding from undisclosed investors on June 29, 2023. The company is a developer of microfluidic flow cytometry devices designed to facilitate simplified biomedical cell analysis and sorting.
Luminopia: The company raised $16 million of Series A venture funding in a deal led by US Venture Partners on June 27, 2023, putting the company’s pre-money valuation at $28 million. ShangBay Capital, The Vertical Group and Broadfin Advisors also participated in the round. The company is a developer of a virtual reality content platform designed to advance a new class of treatments for significant neuro-visual disorders.
Virtual Incision: The company raised an additional $10.9 million of Series C venture funding from undisclosed investors on June 28, 2023, putting the company’s pre-money valuation at $238 million. The company is a developer of robotic-assisted surgery devices.
Centrexion Therapeutics: The company raised $10.3 million of venture funding in the form of convertible debt from undisclosed investors on June 29, 2023. The company is a clinical-stage biopharmaceutical business intended to address the unmet medical need for the treatment of chronic pain.
TwinStrand Biosciences: The company raised $10.3 million of venture funding from undisclosed investors on June 30, 2023. The company is a developer of a deoxyribonucleic acid sequencing therapy designed to identify ultra-low frequency genomic variants that are undetectable by conventional methods.
Memgen: The company raised $8.1 million through a combination of debt and Series A venture funding from undisclosed investors on June 30, 2023, putting the company’s pre-money valuation at $93.1 million. The company is a developer of a clinical-stage biopharmaceutical business designed to develop potentially life-saving viral immunotherapies for patients.
Cytosolix: The company raised $6.8 million of venture funding from BlueYard Capital and undisclosed investors on June 28, 2023. The company is a developer of a biotechnology platform intended to improve small molecule therapy through targeted drug delivery to solid tumors.
Genome Insight: The company raised $4.5 million of venture funding from undisclosed investors on June 27, 2023. The company is a developer of a genome-based big data platform designed to enable personalized precision medicine.
XpertDox: The company is in the process of raising Series A venture funding on June 28, 2023. The company is a developer of a medical coding platform designed to improve access to clinical trials and automate the coding process.
|
